Bakkt Q2 2026: $80.8M GAAP Net Income Driven by $98.5M Non-Cash Transchem Warrant Gain; TTV Guidance of ~$2.5B for Full Year

summarizeSummary

Bakkt's Q2 2026 GAAP net income of $80.8 million was entirely from a non-cash Transchem warrant gain; core operations posted an $11.8 million adjusted EBITDA loss on collapsing revenue. The company guided to ~$2.5 billion in full-year TTV and Q4 2026 product launches, but faces significant execution risk.

check_boxKey Events · Earnings and Guidance · BKKT

• GAAP Net Income Driven by Non-Cash Gain

  Q2 2026 GAAP net income of $80.8 million ($1.96 basic / $1.94 diluted EPS) was entirely driven by a $98.5 million non-cash gain from the change in fair value of Transchem warrants. Excluding this and other non-cash items, adjusted EBITDA loss was $11.8 million.

• Revenue Collapse Continues

  Total revenue fell 70% year-over-year to $170.1 million, reflecting previously disclosed client transitions and industry-wide softness in digital asset trading volumes. Crypto costs and execution fees of $169.3 million nearly offset all revenue.

• Full-Year TTV Guidance of ~$2.5 Billion

  Management expects Total Transacting Volume of approximately $2.5 billion for full-year 2026, implying a massive ramp from the $410.0 million recorded in H1 2026. This assumes successful client integrations and activations in the second half.

• Product Launches Targeted for Q4 2026

  Bakkt Agent Embedded Finance is available for partner integration now, with initial co-branded card programs and Neobank-as-a-Service offerings targeted for Q4 2026. Monthly Active Users are expected to reach ~25,000 by December 2026.

auto_awesomeAnalysis · BKKT · Crypto Assets

Bakkt reported a GAAP net income of $80.8 million, but this was entirely driven by a $98.5 million non-cash gain from the fair value remeasurement of its Transchem warrants — not from operations. The core business remains deeply unprofitable, with an adjusted EBITDA loss of $11.8 million and a 70% revenue collapse to $170.1 million, reflecting client losses and weak crypto trading volumes. The company provided full-year TTV guidance of approximately $2.5 billion, implying a massive ramp in the second half, and expects to launch co-branded card programs and a Neobank-as-a-Service in Q4 2026. Cash stood at $50.7 million with no long-term debt, but the company has been aggressively tapping equity markets, raising $69.6 million in H1 2026 through a registered direct offering and ATM sales. The Transchem warrant position, now valued at $107.9 million on the balance sheet, is a non-cash mark-to-market asset that could swing sharply with the underlying share price. Investors should focus on the adjusted EBITDA loss and the execution risk around the ambitious second-half TTV and product launch targets.